[Angioedema prophylaxis]
- PMID: 30656382
- DOI: 10.1007/s00105-018-4345-9
[Angioedema prophylaxis]
Abstract
Angioedema is a spontaneous, edematous swelling of the deep layers of the skin or mucous membrane. Angioedema in the respiratory tract is potentially life-threatening. The classification of angioedema into mast-cell-mediated (e. g. urticaria) or bradykinin-mediated (e. g. hereditary angioedema) is important for correct and rational treatment. Generally, two therapeutic strategies are available for angioedema treatment. On-demand treatment of angioedema symptoms that already have emerged aims to stop the further development of the attack and, thus, limits the severity and duration of the attack. This strategy is well established in the treatment of patients with hereditary angioedema, whereas in chronic spontaneous urticaria on-demand therapy plays no role in the guideline recommendations. In contrast, the therapeutic strategy of prophylaxis aims to prevent the occurrence of spontaneous and induced attacks as far as possible. Prophylaxis is the sole therapy strategy for chronic urticaria and is applied at all stages of the treatment algorithm. In the case of hereditary angioedema, on-demand therapy can be complemented by prophylaxis after careful and individual indication. In hereditary angioedema, prophylaxis is currently gaining in importance due to improved treatment options. Patients who use a prophylactic regime are much less likely to be forced to wait for the unpredictable occurrence of an attack and then to react with an on-demand treatment. Prophylactic treatment takes place at times determined by the patient himself, in contrast to treatment on an as-needed basis. The loss of unpredictability is a decisive moment in improving the quality of life.
Keywords: C1-Inhibitor deficiency; Chronic spontaneous urticaria; Long-term prophylaxis; On-demand therapy; Short-term prophylaxis.
Similar articles
-
Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema.Transfusion. 2016 May;56(5):1022-9. doi: 10.1111/trf.13462. Epub 2016 Jan 12. Transfusion. 2016. PMID: 26756974
-
Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate.Int Arch Allergy Immunol. 2011;154(4):356-9. doi: 10.1159/000321830. Epub 2010 Oct 26. Int Arch Allergy Immunol. 2011. PMID: 20975289
-
C1-esterase inhibitor (Cinryze®) use in the treatment of pediatric hereditary angioedema.Immunotherapy. 2018 Jun;10(8):635-642. doi: 10.2217/imt-2017-0049. Epub 2018 Mar 23. Immunotherapy. 2018. PMID: 29569504 Review.
-
A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.Immunol Lett. 2017 Sep;189:90-93. doi: 10.1016/j.imlet.2017.05.015. Epub 2017 May 31. Immunol Lett. 2017. PMID: 28577900
-
Hereditary angioedema: an update on causes, manifestations and treatment.Br J Hosp Med (Lond). 2019 Jul 2;80(7):391-398. doi: 10.12968/hmed.2019.80.7.391. Br J Hosp Med (Lond). 2019. PMID: 31283393 Review.
Cited by
-
A Rare Case of Valsartan-Induced Angioedema.Cureus. 2025 Jun 9;17(6):e85623. doi: 10.7759/cureus.85623. eCollection 2025 Jun. Cureus. 2025. PMID: 40636633 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources